Oppenheimer reiterates Veru stock rating ahead of obesity trial data

Oppenheimer maintained an Outperform rating and $24.00 price target for Veru (VERU), citing potential obesity treatment trial results. The stock is down 11% in a week. Veru reported a smaller-than-expected Q3 loss and has sufficient cash for operations. Phase 2b PLATEAU study interim results are expected in Q1 2027.

Original reporting
Published Oct 14, 2026, 11:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 11:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$VERU
Neutral
medium confidence
Mentioned
$VERU
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$VERUNeutralLow
01

Why it matters

The analyst's reiteration could attract short‑term buying interest, but the real catalyst remains the upcoming trial readout.

02

Market read

The article offers a modest rating update without new data; relevance for traders is limited.

03

What to watch

Potential competition from other GLP‑1 adjuncts and the company's cash runway constraints.

Relevance 4/10Novelty 2/10Timing: none

Background

Veru reported a smaller Q3 loss and increased cash, while its Phase 2b PLATEAU study is fully enrolled.

Company-level read

Ticker impact

$VERUNeutralMedium confidence
Context

Oppenheimer reiterated an Outperform rating and $24 price target for Veru ahead of its Phase 2b obesity trial readout.

Expected impact

potential upward pressure as market prices in the upgraded rating and upcoming data expectations

Evidence & confidence

The reiteration adds a higher target but no new data; price move depends on trial outcome.

Market effects

Limited impact on the broader biotech sector; only investors focused on obesity therapeutics may react.

US market only; no regional spillover.

Low; the story is company‑specific.

Counterpoint

The upgrade may be premature without data; the stock could face downside if the trial fails.

Key entities

  • Veru, Inc.

    Biotech firm developing obesity‑adjunct therapy.

  • Oppenheimer

    Equity research firm providing the rating.

Related articles

$VERUMed

Veru presents data on enobosarm for obesity treatment

Veru Inc. (VERU) presented Phase 2b QUALITY study data at ObesityWeek 2026, showing enobosarm 3mg plus semaglutide helped patients aged 65+ with obesity gain lean mass and maintain physical function. The Phase 2b PLATEAU trial, with 239 patients, is ongoing, with interim data expected in Q1 2027. Veru has a clinical supply agreement with Novo Nordisk and a U.S. patent for the combination therapy.

$VERUMedAI 8/10

Veru executive to present obesity drug data at industry conference

Veru Inc. (VERU) will present obesity drug data at ObesityWeek 2026. Dr. Gary Barnette will discuss physical function in older patients using a GLP-1 receptor agonist from the QUALITY study. The company's Phase 2b PLATEAU trial has enrolled 239 patients, exceeding targets. Interim results are expected in Q1 2027, with final data in Q4 2027, according to the company.

$VERUMed

Why is Veru stock gaining today?

Veru Inc. (VERU) shares rose 1.8% after Oppenheimer reiterated its Outperform rating and $24 price target, citing confidence in enobosarm's Phase 2b trial results. The trial, fully enrolled with 239 patients, aims to show lean body mass preservation and fat loss benefits. Veru holds a U.S. patent for the enobosarm-semaglutide combination until 2044. The stock traded at $2.23, below its 52-week high of $7.33 but above its low of $2.05.

$VERUHighAI 8/10

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™)…

VERU INC. (VERU) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib